EdiGene and Neukio to Develop iPSC-Derived NK Cell Therapies
Feb. 9, 2022, BEIJING & SHANGHAI & CAMBRIDGE, Mass. – EdiGene, Inc., a global biotechnology company focused on translating gene-editing technologies into transformative therapies for patients with serious genetic diseases and cancer, and Neukio Biotherapeutics, a biotechnology company focused on the development and commercialization of allogenic iPSC-CAR-NK cell therapies, today announced an R&D collaboration to develop next-generation immune cell therapies. [Read more…]
Exopharm Signs Master Collaborative Agreement to Manufacture Exosomes for Astellas
-
Astellas Institute for Regenerative Medicine (AIRM) is a subsidiary of Astellas Pharma Inc., a top 20 global pharmaceutical company
-
Initial services will seek to validate Exopharm’s LEAP, LOAD and EVPS technology platforms to manufacture exosomes for Astellas, firstly at Exopharm’s facilities in Melbourne followed by the Astellas facilities in Massachusetts USA
-
Future potential collaboration is anticipated following validation
-
This is Exopharm’s first collaboration services agreement with a major pharmaceutical company
StemCyte Reports Successful Phase I Trial Using Cord Blood to Treat Cerebral Stroke
StemCyte Announces Successful Outcome in Phase I Clinical Trial for Treating Acute Cerebral Stroke Using Allogeneic Human Umbilical Cord Blood
StemCyte is a portfolio company of Microbio Group focusing on new drug discovery in cell therapy with operations in the U.S., Taiwan, and India
BALDWIN PARK, Calif., Jan. 26, 2022 — Southern California cord blood therapeutics company StemCyte Inc. is announcing successful preliminary results for Phase I of the company’s clinical trial for treating acute cerebral stroke using monocytes from allogeneic human umbilical cord blood (hUCB). [Read more…]
Excellos Launches as Latest Cell and Gene Therapy CDMO with $15M in Funding
Founded by an Experienced Management Team and Built on the Reach and Infrastructure of the San Diego Blood Bank
SAN DIEGO, January 25, 2022 — Excellos, Incorporated, a cell therapy Contract Development and Manufacturing Organization (CDMO), announces its official corporate launch and closing of $15M in growth funding from Telegraph Hill Partners (THP). Built on the foundation of the San Diego Blood Bank (SDBB), Excellos is focused on supplying cGMP cellular products and services, together with process development and manufacturing expertise to scientists and clinicians working with cell and gene therapies. [Read more…]
- « Previous Page
- 1
- …
- 156
- 157
- 158
- 159
- 160
- …
- 339
- Next Page »